Template:Medications and dosages used in hormone therapy for transgender men
Jump to navigation
Jump to search
| Medication | Brand names | Type | Route | Dosage |
|---|---|---|---|---|
| Testosterone undecanoate | Andriol, Jatenzo | Androgen | Oral | 40–80 mg/2–3x day (with meals) |
| Testosterone | Striant | Androgen | Buccal | 30 mg 2x/day |
| Natesto | Nasal spray | 11 mg 3x/day | ||
| AndroGel, others | Transdermal gel | 25–100 mg/day | ||
| Androderm, others | Transdermal patch | 2.5–10 mg/day | ||
| Axiron | Axillary solution | 30–120 mg/day | ||
| Testopel | Subcutaneous implant | 150–600 mg/3–6 months | ||
| Testosterone enanthate | Delatestryl, others | Androgen | Injection (IM or SC) | 50–100 mg/week or 100–250 mg/2–4 weeks |
| Testosterone cypionate | Depo-Testosterone, others | Androgen | Injection (IM or SC) | 50–100 mg/week or 100–250 mg/2–4 weeks |
| Testosterone isobutyrate | Agovirin Depot | Androgen | Injection (IM or SC) | 50–100 mg/week |
| Mixed testosterone esters | Sustanon 250, others | Androgen | Injection (IM or SC) | 250 mg/2–3 weeks or 500 mg/3–6 weeks |
| Testosterone undecanoate | Aveed, Nebido, others | Androgen | Injection (IM or SC) | 750–1,000 mg/10–14 weeks |
| GnRH analogue | Various | GnRH modulator | Parenteral (various) | Variable |
| Elagolix | Orilissa | GnRH antagonist | Oral | 150 mg/day or 200 mg/twice a day |
| Medroxyprogesterone acetatea | Provera, others | Progestin | Oral | 5–10 mg/day |
| Depo-Provera, others | Injection (IM) | 150 mg/3 months | ||
| Depo-SubQ Provera 104 | Injection (SC) | 104 mg/3 months | ||
| Lynestrenola | Orgametril, others | Progestin | Oral | 5–10 mg/day |
| Finasterideb | Propecia, Proscar | 5α-Reductase inhibitor | Oral | 1 mg/day |
| Dutasterideb | Avodart | 5α-Reductase inhibitor | Oral | 0.5 mg/day |
| Notes: Testes produce 3 to 11 mg testosterone per day (mean 7 mg/day in young men). Footnotes: a = For suppression of menses. b = For prevention/treatment of scalp hair loss. Sources: [1][2][3][4][5][6][7][8][9] | ||||
Template documentationSee also
- Template:Androgen replacement therapy formulations and dosages used in men
- Template:Medications and dosages used in hormone therapy for transgender women
- Template:Androgen replacement therapy formulations and dosages used in women
- Template:Androgen/anabolic steroid dosages for breast cancer
References
- ↑ Hembree, Wylie C; Cohen-Kettenis, Peggy T; Gooren, Louis; Hannema, Sabine E; Meyer, Walter J; Murad, M Hassan; Rosenthal, Stephen M; Safer, Joshua D; Tangpricha, Vin; T’Sjoen, Guy G (2017). "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline". The Journal of Clinical Endocrinology & Metabolism. 102 (11): 3869–3903. doi:10.1210/jc.2017-01658. ISSN 0021-972X.
- ↑ Fabris, B.; Bernardi, S.; Trombetta, C. (2014). "Cross-sex hormone therapy for gender dysphoria". Journal of Endocrinological Investigation. 38 (3): 269–282. doi:10.1007/s40618-014-0186-2. ISSN 1720-8386.
- ↑ Meriggiola, Maria Cristina; Gava, Giulia (2015). "Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen". Clinical Endocrinology. 83 (5): 597–606. doi:10.1111/cen.12753. ISSN 0300-0664.
- ↑ Defreyne, Justine; T’Sjoen, Guy (2019). "Transmasculine Hormone Therapy". Endocrinology and Metabolism Clinics of North America. 48 (2): 357–375. doi:10.1016/j.ecl.2019.01.004. ISSN 0889-8529.
- ↑ Fishman, Sarah L.; Paliou, Maria; Poretsky, Leonid; Hembree, Wylie C. (2019). "Endocrine Care of Transgender Adults". Transgender Medicine. Contemporary Endocrinology. pp. 143–163. doi:10.1007/978-3-030-05683-4_8. ISBN 978-3-030-05683-4. ISSN 2523-3785.
- ↑ Irwig, Michael S (2017). "Testosterone therapy for transgender men". The Lancet Diabetes & Endocrinology. 5 (4): 301–311. doi:10.1016/S2213-8587(16)00036-X. ISSN 2213-8587.
- ↑ Heresová J, Pobisová Z, Hampl R, Stárka L (December 1986). "Androgen administration to transsexual women. II. Hormonal changes". Exp. Clin. Endocrinol. 88 (2): 219–23. doi:10.1055/s-0029-1210600. PMID 3556412.
- ↑ Arif, Tasleem; Dorjay, Konchok; Adil, Mohammad; Sami, Marwa (2017). "Dutasteride in Androgenetic Alopecia: An Update". Current Clinical Pharmacology. 12 (1). doi:10.2174/1574884712666170310111125. ISSN 1574-8847.
- ↑ "Orilissa (elagolix) FDA Label" (PDF). 24 July 2018. Retrieved 31 July 2018.